Source-grounded facts extracted from Acrivon Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Acrivon Therapeutics, Inc. terminated OncoSignature Companion Diagnostic Agreement with Akoya Biosciences, Inc. (a wholly owned subsidiary of Quanterix Corporation) (effective 2026-02-25).
“On February 25, 2026, the Company and Akoya Biosciences, (“Akoya”) a wholly owned subsidiary of Quanterix Corporation (“Quanterix”), entered into a Termination and Transition Agreement pursuant to which they have mutually agreed to terminate (the “termination”) the OncoSignature Companion Diagnostic Agreement, dated June 17, 2022, by and between the Company and Akoya.”
Adam Levy was appointed as Chief Financial Officer at Acrivon Therapeutics, Inc..
“On March 14, 2025, Acrivon Therapeutics, Inc. (the “Company”) appointed Adam Levy, Ph.D., M.B.A., to the position of Chief Financial Officer, effective as of April 1, 2025 (the “Effective Date”).”
Rasmus Holm-Jorgensen resigned as Chief Financial Officer at Acrivon Therapeutics, Inc..
“On March 11, 2025, Rasmus Holm-Jorgensen, the Company’s Chief Financial Officer, notified the Company of his decision to step down from his position, effective April 1, 2025, for personal reasons to pursue another opportunity with a company based in Europe, allowing him to spend more time near his family.”
Earnings Releases
Acrivon Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income $16.5 million.
“Net loss for the quarter ended March 31, 2024 was $16.5 million compared to a net loss of $12.8 million for the same period in 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.